Browse the corpus

Extracorporeal membrane oxygenation (ECMO) provides temporary cardiopulmonary support for patients with life-threatening cardiac or respiratory failure unresponsive to conventional therapy. By diverting blood through an external circuit for oxygenation and carbon dioxide removal, ECMO sustains end-organ perfusion while allowing time for recovery or transition to definitive treatment. Blood exposure to artificial surfaces within the ECMO circuit activates the coagulation cascade, promoting fibrin deposition and thrombus formation. Without anticoagulation, these clots can obstruct circuit components, reduce flow, cause oxygenator failure, or embolize into the bloodstream. Anticoagulation is therefore necessary to preserve circuit function, prevent thromboembolic events, and reduce morbidity and mortality. Unfractionated heparin is the preferred agent due to its rapid onset, reversibility, and clinical familiarity. Direct thrombin inhibitors provide alternatives in patients with heparin-induced thrombocytopenia. Anticoagulation is indicated for most ECMO configurations unless contraindicated by active bleeding or severe coagulopathy. Monitoring strategies, including activated clotting time, anti-Xa levels, and thromboelastography, guide dosing but vary in reliability. Complications such as hemorrhage, thrombocytopenia, and pump head thrombosis require prompt recognition and management. Compared to other mechanical supports, ECMO demands continuous anticoagulation vigilance. Optimal outcomes depend on interprofessional coordination across critical care, perfusion, and nursing teams. This activity for healthcare professionals is designed to enhance learners' competence in administering anticoagulation during ECMO and evaluating suitable candidates for the treatment. Participants will broaden their grasp of thrombosis pathophysiology, anticoagulant selection, and monitoring strategies to prevent complications. Improved skills will equip clinicians to collaborate successfully within interprofessional teams caring for individuals with cardiorespiratory failure. Objectives: Evaluate patients for suitability for extracorporeal membrane oxygenation based on clinical and diagnostic features. Select the appropriate extracorporeal membrane oxygenation configuration based on patient indications and contraindications.

This activity for healthcare professionals is designed to enhance learners' competence in administering anticoagulation during ECMO and evaluating suitable candidates for the treatment. Participants will broaden their grasp of thrombosis pathophysiology, anticoagulant selection, and monitoring strategies to prevent complications. Improved skills will equip clinicians to collaborate successfully within interprofessional teams caring for individuals with cardiorespiratory failure. Objectives: Evaluate patients for suitability for extracorporeal membrane oxygenation based on clinical and diagnostic features. Select the appropriate extracorporeal membrane oxygenation configuration based on patient indications and contraindications. Apply effective anticoagulation monitoring strategies during extracorporeal membrane oxygenation to reduce the risk of complications. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for individuals receiving extracorporeal membrane oxygenation. Access free multiple choice questions on this topic.

Extracorporeal membrane oxygenation (ECMO) has become an increasingly utilized modality in the treatment of critically ill patients experiencing severe cardiac or respiratory failure. As access to ECMO continues to expand globally, clinicians across multiple specialties are encountering this life-sustaining intervention in various settings. The primary goal of ECMO is to maintain systemic perfusion and gas exchange in patients with cardiopulmonary failure, serving as a bridge to recovery, transplantation, or prolonged mechanical support. ECMO is typically categorized into 2 configurations: venovenous (VV), which supports pulmonary function, and venoarterial (VA), which supports both pulmonary and circulatory function. Although ECMO can be lifesaving, it carries substantial risk, particularly related to bleeding and thromboembolic complications. Thromboembolism remains a leading cause of morbidity and circuit failure, reinforcing the necessity of precise anticoagulation.[1][2] A clear understanding of ECMO circuit physiology and coagulation disturbances during support is essential for reducing complications and improving outcomes. Mastery of pharmacologic approaches, monitoring methods, and interprofessional coordination enhances the safety and efficacy of anticoagulation. This educational activity provides a detailed review of anticoagulation in ECMO, promotes evidence-based practices, and advances team-based competence in treating patients supported with ECMO.

Complications Arising from Venovenous Extracorporeal Membrane Oxygenation In VV-ECMO, complications frequently result from inadequate circuit flow relative to elevated native cardiac output, as seen in sepsis. When cardiac output surpasses ECMO flow, incomplete mixing of oxygenated and deoxygenated blood may lead to persistent hypoxemia despite optimal ventilator settings and functional circuit performance. Complications Resulting from Venoarterial Extracorporeal Membrane Oxygenation VA-ECMO presents unique challenges related to retrograde arterial flow. Femoral artery cannulation may impair distal limb perfusion and increase the risk of ischemia. This complication may be reduced by placing selective reperfusion catheters or by using axillary artery access. Retrograde flow also increases left ventricular afterload, which may lead to ventricular distension, pulmonary edema, and reduced coronary perfusion.[13] Clinical indicators include diminished arterial pulsatility, elevated left ventricular end-diastolic pressure, and ventricular arrhythmias. Management strategies to decompress the left ventricle include placement of an Impella device, surgical venting, or atrial septostomy to facilitate forward flow. Thrombosis and Heparin-Induced Thrombocytopenia Thromboembolic events remain a concern during both VV-ECMO and VA-ECMO, particularly in regions of low flow, stagnant zones, and within the oxygenator. Hemolysis from mechanical shear stress further increases thrombogenic risk. Pump head thrombosis may present with elevated plasma-free hemoglobin levels exceeding 500 mg/dL and a platelet count reduction greater than 50%, often necessitating urgent circuit replacement. Heparin-induced thrombocytopenia is a potentially life-threatening, immune-mediated complication of heparin therapy. Suspicion should arise with a platelet decline of 50% or more occurring within 5 to 14 days of heparin initiation.[14] Diagnosis requires laboratory confirmation, such as enzyme-linked immunosorbent assay or serotonin release assay. Once confirmed, heparin must be discontinued and replaced with a direct thrombin inhibitor. Other Complications

Heparin-induced thrombocytopenia is a potentially life-threatening, immune-mediated complication of heparin therapy. Suspicion should arise with a platelet decline of 50% or more occurring within 5 to 14 days of heparin initiation.[14] Diagnosis requires laboratory confirmation, such as enzyme-linked immunosorbent assay or serotonin release assay. Once confirmed, heparin must be discontinued and replaced with a direct thrombin inhibitor. Other Complications Additional risks include bleeding at cannulation sites or inside the body, particularly within the gastrointestinal tract or intracranial space. Infection, air embolism, circuit component failure, and progressive hemolysis also pose significant risks. Early recognition and structured, protocol-driven management by an interprofessional team are essential to reduce morbidity and improve patient outcomes.

The safe and effective use of ECMO depends on continuous interprofessional collaboration. From initiation through weaning, successful management requires coordinated efforts among surgical, critical care, nursing, perfusion, and pharmacy teams. A cardiothoracic surgeon typically performs cannulation and initiates support. Perfusionists operate the ECMO circuit at the bedside, adjusting parameters in real time and monitoring for complications such as oxygenator failure, hemolysis, and thrombus formation to ensure uninterrupted function. Intensive care physicians, physician assistants, and nurse practitioners oversee daily management, including hemodynamic support, ventilator adjustments, anticoagulation titration, and multisystem care. Pharmacists assist with anticoagulant dosing, heparin resistance, and drug-drug interaction management. Nurses provide one-to-one bedside care, conduct frequent neurologic assessments, inspect cannula sites, and monitor circuit alarms and patient responses. Anticoagulation oversight, hourly monitoring, and arterial blood gas interpretation are shared responsibilities. When clinical deterioration occurs, early recognition and rapid response by any team member can lead to lifesaving intervention. Structured communication tools, standardized handoffs, and mutual respect across disciplines enhance team function and reduce complications. Flattened hierarchy and shared accountability strengthen interprofessional collaboration and improve both the safety and outcomes of ECMO therapy.

Responsibilities of Bedside Staff to the Patient Caring for patients on ECMO typically requires a staffing model that approximates 1:1 care for both the individual and the ECMO circuit. The circuit is treated as a second patient, demanding continuous monitoring and immediate intervention when complications arise. Patient Monitoring and Intervention Patient movement during imaging or repositioning should be coordinated with multiple team members to reduce the risk of complications. Daily chest radiographs must be obtained to assess lung fields and confirm the position of cannulas, endotracheal tubes, chest tubes, and central lines. Cannula sites should be inspected frequently for signs of bleeding, infection, or mechanical issues such as kinking or dislodgement. Neurologic examinations must be performed every 1 to 2 hours due to the elevated risk of intracranial hemorrhage, stroke, and seizures. These assessments should include evaluation of pupillary reflexes, spontaneous respirations, pain responses, and, in pediatric patients, fontanelle size and autonomic signs such as episodic tachycardia or hypertension, which may indicate subclinical seizures or intracranial bleeding. Ventilator settings should be adjusted based on ECMO circuit performance. Since ventilation is often significantly reduced while on ECMO, declining gas exchange may indicate thrombus formation within the oxygenator. Arterial blood gases are typically monitored every 30 to 60 minutes during initiation, then every 2 to 4 hours once stable. Endotracheal suctioning is performed as needed. The presence of bright red blood in the endotracheal tube may suggest pulmonary hemorrhage, which may respond to increased positive end-expiratory pressure. Renal function and hemolysis should be continuously monitored. Urine output and color must be documented regularly. Gross hematuria may result from anticoagulation. Plasma-free hemoglobin levels exceeding 500 mg/dL, accompanied by a decline in platelet count, raise suspicion for pump head thrombosis.[15] Levels above 53 mg/dL have been associated with increased risk for renal replacement therapy and mortality.[16] Responsibilities of Bedside Staff to the Extracorporeal Membrane Oxygenation Circuit

Renal function and hemolysis should be continuously monitored. Urine output and color must be documented regularly. Gross hematuria may result from anticoagulation. Plasma-free hemoglobin levels exceeding 500 mg/dL, accompanied by a decline in platelet count, raise suspicion for pump head thrombosis.[15] Levels above 53 mg/dL have been associated with increased risk for renal replacement therapy and mortality.[16] Responsibilities of Bedside Staff to the Extracorporeal Membrane Oxygenation Circuit The ECMO circuit should be inspected regularly for signs of clot formation, tubing discoloration, or structural abnormalities. Circuit performance must be evaluated by trending transmembrane pressures, bladder pressures, fraction of inspired oxygen, and sweep gas flow. Audible circuit "chatter" should be recognized as a potential indicator of hypovolemia or low venous return, which may result from inadequate preload, pneumothorax, or cardiac tamponade. System alarms must be addressed without delay. These alerts may be triggered by patient agitation, volume depletion, or cannula kinking. Rapid evaluation is required to prevent circuit compromise and ensure uninterrupted support.